Journal of Biotechnology & Biomaterials
Open Access

Research Article

Anti-Inflammatory and Regenerative Potential of Probiotics to Combat Inflammatory Bowel Disease (IBD)

Department of Zoology, Immunology and Regenerative Medicine Research Laboratory, University of Calcutta, 35, Ballygunge Circular Road, Kolkata- 700019, West Bengal, India

Corresponding Author:

Ena Ray Banerjee
University of Calcutta, Zoology
35 Ballygunge Circular Road, Kolkata, West Bengal 700019, India
Tel: 91-33-24615445
Fax: 91-33-24614849
E-mail: enarb1@gmail.com

Received date:: May 06 2015; Accepted date:: May 20, 2015; Published date:: May 28, 2015

Citation: Das R, Trafadar B, Das P, Kar S, Mitra S, et al. (2015) Anti-Inflammatory and Regenerative Potential of Probiotics to Combat Inflammatory Bowel Disease (IBD). J Biotechnol Biomater 5:181. doi:10.4172/2155-952X.1000181

Copyright: © 2015 Das R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Inflammatory Bowel Diseases (IBD) is a chronic disorder of the gastrointestinal (GI) tract characterized by body weight loss, hemorrhage, lower abdominal pain and diarrhea. Indiscriminate use of antibiotics and modern life style disrupts microbial ecosystem of the human GI tract which leads to IBD. No disease modifying treatment exists for IBD which are both inflammatory and degenerative in nature. This study aimed at evaluating anti-inflammatory and pro-regenerative potential of probiotics in preclinical IBD. For in vitro study, inflammation was induced on RAW264.7 cell treated with 3% DSS (w/v), 1μg/ml LPS and 600ng/ml PMA. Novel combinations of probiotics were administrated on inflamed cell to measure their anti-inflammatory role. Cell viability and NO release assay were also done. For in vivo study, composite IBD phenotype was developed by 3% DSS by oral gavage (40μl) for 7 days and our probiotic combo was administered over 7 days (at 108 CFU/200μl) of DSS induction in Balb/c mice. Body weight, NO and ascorbic acid production by cells harvested from key lymphoid organs post-mortem, and histological studies were done to assess inflammation. We found cell viability increased from 30% to 92.5 % and NO concentration was reduced 2.22 fold after administration of probiotics. Mouse body weight (BW) reduced by 30.2% and 35.4% on 7th and 14th day respectively following DSS induction. Oral probiotics increased mouse BW in by 47%. NO concentration decreased 1.19 fold and 2.17 fold in colon and spleen tissue and ascorbic acid concentration increased 1.82 fold and 5.50 fold in colon and spleen tissue respectively. Clonogenic potential of intestine and spleen was decreased 2.38 fold and 2.34 fold in DSS treated mouse on 7th and 14th day respectively but it was increased 1.29 fold and 1.36 fold on 7th and 14th day respectively after probiotics administration in DSS treated mice. This indicates greater clonogenicity in intestine and spleen of probiotic treated mice as opposed to the reduced colony count of progenitor’s post-DSS only mice. Overall, orally administered probiotics showed anti-inflammatory and pro-regenerative action to revive the cells and tissues of DSS treated mice in which all symptoms of IBD were detected earlier. This study validates the use of combination of probiotic microbial strains supplemented in food (curd, yoghurt) as nutraceuticals and possible therapeutic as well as prophylactic to combat inflammation and degeneration in IBD.

Keywords